Pharmaceuticals, Biotechnology and Life Sciences
Mylan’s second quarter performance was strong as the company has delivered or exceeded on expectations across all financial metrics, the company’s CEO Heather Bresch said in a press release Monday.
Study Met Its Co-Primary Endpoint of Overall Survival with Opdivo® (nivolumab) Plus Low Dose Yervoy® (ipilimumab) vs. Chemotherapy in First-Line Non-Small Cell Lung Cancer Patients Whose Tumors Express PD-L1 ≥1%
Proteostasis Therapeutics has started with the phase 2 study of cystic fibrosis treatment by dosing the first patient, after a successful Phase 1 test of PTI’s combinations.
BioCity, and Oxford AHSN are launching a new Accelerator Programme in Berkshire and South Oxfordshire to catalyse growth in Thames Valley’s world-class health and life sciences cluster by supporting the development of start-ups, spin-outs and growth companies across the region’s research, clinical and commercial base.
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on July 23, 2019 the Compensation Committee of…
Inovio Pharmaceuticals published its positive results from the first-in-human trial of its vaccine against the Middle East Respiratory Syndrome Coronavirus…
LONDON–(BUSINESS WIRE)–ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today…
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first…
DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a global provider of drug and device development and commercialisation services to the pharmaceutical, biotechnology…
ImaginAb has started the clinical trial of its lead product, CD8 tracer Zr-Df-IAB22M2C, a first in class imaging agent that visualizes the immune system using non-invasive, whole-body in vivo PET imaging of CD8 T cells.